Medication
Cefoxitin for Injection
DIN 02128187 · Teva Canada Limited Likely a generic
What it is
- Active ingredients
- Cefoxitin — 1 g
- Form and routes
- Powder For Solution · Intramuscular, Intravenous
- Schedule
- PRESCRIPTION
- Authorised since
- 1995-12-31
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
No other medication authorised in Canada shares this active ingredient.
Health Canada groups products by their active ingredients. No other marketed product shares this one’s group, which usually means it is still the only authorised version — not that alternatives were hidden or missed.
Watch this medication
Ontario Drug Benefit coverage
As of 31 July 2026Off-formulary interchangeable Part III-B
Ontario has designated this product interchangeable with a brand product, but it is not an ODB benefit — Part III-B, Off-Formulary Interchangeable. Ontario does not pay for it under the benefit list.
It may be funded through the Exceptional Access Program, which needs a patient-specific application from a prescriber and is decided case by case.
- What ODB pays per unit
- $10.6000
This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Reported side effects
RxMonitor does not show reported side effects.
Health Canada collects voluntary reports of suspected side effects in the Canada Vigilance database. RxMonitor does not summarise them, because a count of reports is not a rate and the most-reported term for a medication is often the condition it is prescribed for — for a reliever inhaler, the most reported term is asthma. Nothing here should be read as a list of this medication’s side effects, or as evidence that it has few. The product monograph and a pharmacist are the sources for that.
How it is classified
- Anatomical main group
- Anti-infectives for systemic use
- ATC code
- J01DC01
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of J01DC01, see the WHO ATC/DDD Index.
Recalls and safety alerts
As of 12 August 2026Archived by Health Canada
1 older notice naming this product has been archived. These are a record of what happened, not current warnings.
Matched on the product name at the start of the notice.
This list may be incomplete. Health Canada’s recalls data carries no DIN, so notices are matched on wording alone. Search Health Canada recalls for Cefoxitin for Injection → How RxMonitor matches recalls, and how often it fails
Source: Health Canada — Recalls and Safety Alerts. Data current as of 2026-08-12. Matched on product name, not on DIN — the feed carries none.